Stock Events

Stock Events

Nektar Therapeutics 

€71.52
84
-€2.1-2.85% Tuesday 19:55

Statistics

Day High
74.26
Day Low
71.52
52W High
87.5
52W Low
7.73
Volume
-
Avg. Volume
-
Mkt Cap
0
P/E Ratio
-
Dividend Yield
-
Dividend
-

Upcoming

Earnings

7MayExpected
Q4 2025
Next
-2.15
-1.88
-1.62
-1.35
Expected EPS
-1.35035910633
Actual EPS
N/A

People Also Follow

This list is based on the watchlists of people on Stock Events who follow ITH0.STU. It's not an investment recommendation.

Competitors

This list is an analysis based on recent market events. It's not an investment recommendation.
Bristol-Myers Squibb
BMY
Mkt Cap118.87B
Bristol-Myers Squibb competes in the oncology and immunology sectors, directly challenging Nektar's therapeutic areas.
Merck
MRK
Mkt Cap277.02B
Merck is a leader in developing cancer treatments, including immunotherapy drugs that compete with Nektar's pipeline.
Pfizer
PFE
Mkt Cap149.77B
Pfizer has a broad portfolio of drugs in oncology and immunology, making it a direct competitor to Nektar Therapeutics.
Gilead Sciences
GILD
Mkt Cap163.4B
Gilead Sciences focuses on innovative therapies in areas like oncology, directly competing with Nektar's research and development focus.
AMGEN
AMGN
Mkt Cap178B
Amgen's focus on novel therapeutics in oncology and inflammation puts it in direct competition with Nektar Therapeutics.
Regeneron Pharmaceuticals
REGN
Mkt Cap73.54B
Regeneron Pharmaceuticals competes in the biopharmaceutical space, focusing on immunology and oncology, similar to Nektar's interests.
Incyte
INCY
Mkt Cap19.36B
Incyte Corporation specializes in oncology and inflammation, competing with Nektar in the development of cancer and autoimmune disease treatments.
Biogen
BIIB
Mkt Cap27.62B
Biogen's focus on novel therapies, including work in immunology, places it as a competitor to Nektar Therapeutics.
Exelixis
EXEL
Mkt Cap11.1B
Exelixis is focused on developing small molecule therapies for cancer, directly competing with Nektar's oncology pipeline.

About

Nektar Therapeutics, a biopharmaceutical company, focuses on discovering and developing medicines in the field of immunotherapy in the United States and internationally. It develops rezpegaldesleukin, which is in Phase 2b to treat underlying immune system imbalance in people with autoimmune disorders and inflammatory diseases; NKTR-0165 to treat ulcerative colitis, vitiligo, and multiple sclerosis; NKTR-0166 to treat autoimmune disease; NKTR-422 to treat fibrotic diseases; and NKTR-255 to treat solid tumors and large b-cell lymphoma. It has collaboration agreements with Takeda Pharmaceutical Company Ltd.; AstraZeneca AB; UCB Pharma; F. Hoffmann-La Roche Ltd; Bausch Health Companies Inc.; Pfizer Inc.; UCB Pharma (Biogen); Bristol-Myers Squibb Company; and Merck KGaA. The company was incorporated in 1990 and is headquartered in San Francisco, California.
Show more...
CEO
Mr. Howard W. Robin
Employees
63
Country
United States
ISIN
US6402683063

Listings

F
DE
ITH0.F
XNAS
US
NKTR
STU
DE
ITH0.STU
MU
DE
ITH0.MU

0 Comments

Share your thoughts

FAQ

What is Nektar Therapeutics stock price today?▼
The current price of ITH0.STU is €71.52 EUR — it has decreased by -2.85% in the past 24 hours. Watch Nektar Therapeutics stock price performance more closely on the chart.
What is Nektar Therapeutics stock ticker?▼
Depending on the exchange, the stock ticker may vary. For instance, on exchange Nektar Therapeutics stocks are traded under the ticker ITH0.STU.
Is Nektar Therapeutics stock price growing?▼
ITH0.STU stock has risen by +0.42% compared to the previous week, the month change is a +7.55% rise, over the last year Nektar Therapeutics has showed a +749.15% increase.
When is the next Nektar Therapeutics earnings date?▼
Nektar Therapeutics is going to release the next earnings report on May 07, 2026.
What were Nektar Therapeutics earnings last quarter?▼
ITH0.STU earnings for the last quarter are -1.55 EUR per share, whereas the estimation was -2.15 EUR resulting in a +28.06% surprise. The estimated earnings for the next quarter are N/A EUR per share.
How many employees does Nektar Therapeutics have?▼
As of May 06, 2026, the company has 63 employees.
In which sector is Nektar Therapeutics located?▼
Nektar Therapeutics operates in the Other sector.
When did Nektar Therapeutics complete a stock split?▼
The last stock split for Nektar Therapeutics was on June 09, 2025 with a ratio of 1:15.
Where is Nektar Therapeutics headquartered?▼
Nektar Therapeutics is headquartered in San Francisco, United States.